Zurück zu Projekte

14785.1 PFLS-LS

14785.1 PFLS-LS

Zusammenfassung

Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders

Weitere Texte

Abstract

The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.

Beteiligte

Graham Dixon

Wirtschaftspartner

graham.dixon@addextherapeutics.com

Addex Pharmaceuticals SA Graham Dixon Chemin des Aulx 12 1228 Plan-les-Ouates GE CH

Ron Stoop

Kontaktperson

Ron.Stoop@unil.ch

CHUV Centre Hospitalier Universitaire Va Centre for Psychiatric Neuroscience Ron Stoop Hôpital de Cery / Route de Cery 1005 Lausanne VD CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-05-31
Enddatum
2015-11-30
Bewilligte Gesamtkosten
CHF 708030.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%